Kimberly P Newton1,2, Joel E Lavine3, Laura Wilson4,5, Cynthia Behling1,6, Miriam B Vos7, Jean P Molleston8, Philip Rosenthal9, Tamir Miloh10, Mark H Fishbein11, Ajay K Jain12, Karen F Murray13, Jeffrey B Schwimmer1,2. 1. Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, CA. 2. Division of Gastroenterology, Department of Pediatrics, Rady Children's Hospital, San Diego, CA. 3. Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Columbia University, New York, NY. 4. Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD. 5. Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD. 6. Department of Pathology, Sharp Medical Center, San Diego, CA. 7. Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA. 8. Department of Pediatrics, Riley Children's Hospital, Indianapolis, IN. 9. Departments of Pediatrics & Surgery, University of California, San Francisco, CA. 10. Department of Pediatrics, Texas Children's Hospital, Houston, TX. 11. Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL. 12. Department of Pediatrics, Saint Louis University, St. Louis, MI. 13. Department of Pediatrics, Cleveland Clinic Children's Hospital, Cleveland, OH.
Abstract
BACKGROUND AND AIMS: Predictive, noninvasive tools are needed to monitor key features of nonalcoholic fatty liver disease (NAFLD) in children that relate to improvement in liver histology. The purpose of this study was to evaluate the relationship between liver chemistries and liver histology using data from the CyNCh (Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children) clinical trial. APPROACH AND RESULTS: This study included 146 children. Improvement in liver histology, defined as decrease in nonalcoholic fatty liver disease (NAFLD) Activity Score ≥2 points without worsening of fibrosis, occurred in 43 participants (30%). There were 46 participants with borderline zone 1 nonalcoholic steatohepatitis (NASH) at baseline, with resolution in 28% (12 of 46). Multivariate models were constructed using baseline and change in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT) at 52 weeks, for improvement in (1) liver histology primary outcome, (2) borderline zone 1 NASH, and (3) fibrosis. For improvement in histology, the model (P < 0.0001) retained baseline and change in GGT (area under the receiver operating characteristic [AUROC], 0.79; 95% confidence interval [CI], 0.71-0.87). For borderline zone 1 NASH, the model (P = 0.0004) retained baseline and change in ALT (AUROC, 0.80; 95% CI, 0.67-0.93). For fibrosis, the model (P < 0.001) retained baseline and change in ALT (AUROC, 0.80; 95% CI, 0.67-0.93). Additional clinical parameters were added to the models using Akaike's information criterion selection, and significantly boosted performance: improvement in histology with AUROC of 0.89 (95% CI, 0.82-0.95), borderline zone 1 NASH with AUROC of 0.91 (95% CI, 0.83-0.99), and fibrosis with AUROC of 0.89 (95% CI, 0.82-0.94). Models were validated using data from the TONIC (Treatment of Nonalcoholic Fatty Liver Disease in Children) trial. CONCLUSIONS: In children with NAFLD, dynamic changes in serum ALT and GGT are associated with change in liver histology and appear to be powerful indicators of histological response.
BACKGROUND AND AIMS: Predictive, noninvasive tools are needed to monitor key features of nonalcoholic fatty liver disease (NAFLD) in children that relate to improvement in liver histology. The purpose of this study was to evaluate the relationship between liver chemistries and liver histology using data from the CyNCh (Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children) clinical trial. APPROACH AND RESULTS: This study included 146 children. Improvement in liver histology, defined as decrease in nonalcoholic fatty liver disease (NAFLD) Activity Score ≥2 points without worsening of fibrosis, occurred in 43 participants (30%). There were 46 participants with borderline zone 1 nonalcoholic steatohepatitis (NASH) at baseline, with resolution in 28% (12 of 46). Multivariate models were constructed using baseline and change in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT) at 52 weeks, for improvement in (1) liver histology primary outcome, (2) borderline zone 1 NASH, and (3) fibrosis. For improvement in histology, the model (P < 0.0001) retained baseline and change in GGT (area under the receiver operating characteristic [AUROC], 0.79; 95% confidence interval [CI], 0.71-0.87). For borderline zone 1 NASH, the model (P = 0.0004) retained baseline and change in ALT (AUROC, 0.80; 95% CI, 0.67-0.93). For fibrosis, the model (P < 0.001) retained baseline and change in ALT (AUROC, 0.80; 95% CI, 0.67-0.93). Additional clinical parameters were added to the models using Akaike's information criterion selection, and significantly boosted performance: improvement in histology with AUROC of 0.89 (95% CI, 0.82-0.95), borderline zone 1 NASH with AUROC of 0.91 (95% CI, 0.83-0.99), and fibrosis with AUROC of 0.89 (95% CI, 0.82-0.94). Models were validated using data from the TONIC (Treatment of Nonalcoholic Fatty Liver Disease in Children) trial. CONCLUSIONS: In children with NAFLD, dynamic changes in serum ALT and GGT are associated with change in liver histology and appear to be powerful indicators of histological response.
Authors: Brent A Neuschwander-Tetri; Jeanne M Clark; Nathan M Bass; Mark L Van Natta; Aynur Unalp-Arida; James Tonascia; Claudia O Zein; Elizabeth M Brunt; David E Kleiner; Arthur J McCullough; Arun J Sanyal; Anna Mae Diehl; Joel E Lavine; Naga Chalasani; Kris V Kowdley Journal: Hepatology Date: 2010-09 Impact factor: 17.425
Authors: Raj Vuppalanchi; Ajay K Jain; Ross Deppe; Katherine Yates; Megan Comerford; Howard C Masuoka; Brent A Neuschwander-Tetri; Rohit Loomba; Elizabeth M Brunt; David E Kleiner; Jean P Molleston; Jeffrey B Schwimmer; Joel E Lavine; James Tonascia; Naga Chalasani Journal: Clin Gastroenterol Hepatol Date: 2014-05-17 Impact factor: 11.382
Authors: Elizabeth L Yu; Shahrokh Golshan; Kathryn E Harlow; Jorge E Angeles; Janis Durelle; Nidhi P Goyal; Kimberly P Newton; Mary Catherine Sawh; Jonathan Hooker; Ethan Z Sy; Michael S Middleton; Claude B Sirlin; Jeffrey B Schwimmer Journal: J Pediatr Date: 2018-12-14 Impact factor: 4.406
Authors: Amanda Cheung; Brent A Neuschwander-Tetri; David E Kleiner; Elmer Schabel; Mary Rinella; Stephen Harrison; Vlad Ratziu; Arun J Sanyal; Rohit Loomba; Sophie Jeannin Megnien; Richard Torstenson; Veronica Miller Journal: Hepatology Date: 2019-11 Impact factor: 17.425
Authors: David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal Journal: Hepatology Date: 2005-06 Impact factor: 17.425
Authors: Joel E Lavine; Jeffrey B Schwimmer; Mark L Van Natta; Jean P Molleston; Karen F Murray; Philip Rosenthal; Stephanie H Abrams; Ann O Scheimann; Arun J Sanyal; Naga Chalasani; James Tonascia; Aynur Ünalp; Jeanne M Clark; Elizabeth M Brunt; David E Kleiner; Jay H Hoofnagle; Patricia R Robuck Journal: JAMA Date: 2011-04-27 Impact factor: 56.272
Authors: Danielle M Fernandes; Vivek Pantangi; Muhammad Azam; Marcela Salomao; Alina C Iuga; Jay H Lefkowitch; James Gill; Raffaella Morotti; Joel E Lavine; Ali A Mencin Journal: J Pediatr Date: 2018-06-11 Impact factor: 4.406
Authors: Jean P Molleston; Jeffrey B Schwimmer; Katherine P Yates; Karen F Murray; Oscar W Cummings; Joel E Lavine; Elizabeth M Brunt; Ann O Scheimann; Aynur Unalp-Arida Journal: J Pediatr Date: 2013-12-19 Impact factor: 4.406
Authors: Miriam B Vos; Mark L Van Natta; Niviann M Blondet; Srinivasan Dasarathy; Mark Fishbein; Paula Hertel; Ajay K Jain; Saul J Karpen; Joel E Lavine; Saeed Mohammad; Laura A Miriel; Jean P Molleston; Marialena Mouzaki; Arun Sanyal; Emily P Sharkey; Jeffrey B Schwimmer; James Tonascia; Laura A Wilson; Stavra A Xanthakos Journal: Hepatology Date: 2022-02-28 Impact factor: 17.298